[2]
Stasi R, How to approach thrombocytopenia. Hematology. American Society of Hematology. Education Program. 2012;
[PubMed PMID: 23233580]
[3]
Rodeghiero F,Stasi R,Gernsheimer T,Michel M,Provan D,Arnold DM,Bussel JB,Cines DB,Chong BH,Cooper N,Godeau B,Lechner K,Mazzucconi MG,McMillan R,Sanz MA,Imbach P,Blanchette V,Kühne T,Ruggeri M,George JN, Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood. 2009 Mar 12;
[PubMed PMID: 19005182]
[5]
Myers B, Diagnosis and management of maternal thrombocytopenia in pregnancy. British journal of haematology. 2012 Jul;
[PubMed PMID: 22551110]
[6]
Fogerty AE, Thrombocytopenia in Pregnancy: Mechanisms and Management. Transfusion medicine reviews. 2018 Oct;
[PubMed PMID: 30177431]
[7]
D'Andrea G,Chetta M,Margaglione M, Inherited platelet disorders: thrombocytopenias and thrombocytopathies. Blood transfusion = Trasfusione del sangue. 2009 Oct;
[PubMed PMID: 20011639]
[8]
Chaudhary RK,Nepal C,Khanal N,Pathak R,Giri S,Bhatt VR, Management and Outcome of Heparin-Induced Thrombocytopenia in Pregnancy: A Systematic Review. Cardiovascular
[PubMed PMID: 26695420]
Level 1 (high-level) evidence
[10]
Piatek CI,El-Hemaidi I,Feinstein DI,Liebman HA,Akhtari M, Management of immune-mediated cytopenias in pregnancy. Autoimmunity reviews. 2015 Sep;
[PubMed PMID: 25981747]
[11]
Webert KE,Mittal R,Sigouin C,Heddle NM,Kelton JG, A retrospective 11-year analysis of obstetric patients with idiopathic thrombocytopenic purpura. Blood. 2003 Dec 15;
[PubMed PMID: 12947011]
Level 2 (mid-level) evidence
[13]
Abildgaard U, Heimdal K. Pathogenesis of the syndrome of hemolysis, elevated liver enzymes, and low platelet count (HELLP): a review. European journal of obstetrics, gynecology, and reproductive biology. 2013 Feb:166(2):117-23. doi: 10.1016/j.ejogrb.2012.09.026. Epub 2012 Oct 26
[PubMed PMID: 23107053]
[14]
Nelson DB,Yost NP,Cunningham FG, Acute fatty liver of pregnancy: clinical outcomes and expected duration of recovery. American journal of obstetrics and gynecology. 2013 Nov;
[PubMed PMID: 23860212]
Level 2 (mid-level) evidence
[15]
Allen AM,Kim WR,Larson JJ,Rosedahl JK,Yawn BP,McKeon K,Hay JE, The Epidemiology of Liver Diseases Unique to Pregnancy in a US Community: A Population-Based Study. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association. 2016 Feb;
[PubMed PMID: 26305066]
[16]
Moatti-Cohen M,Garrec C,Wolf M,Boisseau P,Galicier L,Azoulay E,Stepanian A,Delmas Y,Rondeau E,Bezieau S,Coppo P,Veyradier A, Unexpected frequency of Upshaw-Schulman syndrome in pregnancy-onset thrombotic thrombocytopenic purpura. Blood. 2012 Jun 14;
[PubMed PMID: 22547583]
[17]
Scully M, Thrombotic Thrombocytopenic Purpura and Atypical Hemolytic Uremic Syndrome Microangiopathy in Pregnancy. Seminars in thrombosis and hemostasis. 2016 Oct;
[PubMed PMID: 27648610]
[18]
Scully M,Thomas M,Underwood M,Watson H,Langley K,Camilleri RS,Clark A,Creagh D,Rayment R,Mcdonald V,Roy A,Evans G,McGuckin S,Ni Ainle F,Maclean R,Lester W,Nash M,Scott R,O Brien P, Thrombotic thrombocytopenic purpura and pregnancy: presentation, management, and subsequent pregnancy outcomes. Blood. 2014 Jul 10;
[PubMed PMID: 24859360]
[19]
Erez O,Mastrolia SA,Thachil J, Disseminated intravascular coagulation in pregnancy: insights in pathophysiology, diagnosis and management. American journal of obstetrics and gynecology. 2015 Oct
[PubMed PMID: 25840271]
[20]
McCrae KR, Thrombocytopenia in pregnancy: differential diagnosis, pathogenesis, and management. Blood reviews. 2003 Mar;
[PubMed PMID: 12490206]
[21]
Freedman J,Musclow E,Garvey B,Abbott D, Unexplained periparturient thrombocytopenia. American journal of hematology. 1986 Apr;
[PubMed PMID: 3953558]
[22]
Lattuada A,Rossi E,Calzarossa C,Candolfi R,Mannucci PM, Mild to moderate reduction of a von Willebrand factor cleaving protease (ADAMTS-13) in pregnant women with HELLP microangiopathic syndrome. Haematologica. 2003 Sep;
[PubMed PMID: 12969811]
[23]
Sánchez-Luceros A,Farías CE,Amaral MM,Kempfer AC,Votta R,Marchese C,Salviú MJ,Woods AI,Meschengieser SS,Lazzari MA, von Willebrand factor-cleaving protease (ADAMTS13) activity in normal non-pregnant women, pregnant and post-delivery women. Thrombosis and haemostasis. 2004 Dec;
[PubMed PMID: 15583740]
[24]
Zhang X,Zhao Y,Li X,Han P,Jing F,Kong Z,Zhou H,Qiu J,Li L,Peng J,Hou M, Thrombopoietin: a potential diagnostic indicator of immune thrombocytopenia in pregnancy. Oncotarget. 2016 Feb 16;
[PubMed PMID: 26840092]
Level 2 (mid-level) evidence
[25]
Li J,Sullivan JA,Ni H, Pathophysiology of immune thrombocytopenia. Current opinion in hematology. 2018 Sep;
[PubMed PMID: 30015642]
Level 3 (low-level) evidence
[26]
George JN,Nester CM, Syndromes of thrombotic microangiopathy. The New England journal of medicine. 2014 Nov 6;
[PubMed PMID: 25372103]
[29]
Cines DB,Blanchette VS, Immune thrombocytopenic purpura. The New England journal of medicine. 2002 Mar 28;
[PubMed PMID: 11919310]
[30]
Devos T,Meers S,Boeckx N,Gothot A,Deeren D,Chatelain B,Chatelain C,Devalet B, Diagnosis and management of PNH: Review and recommendations from a Belgian expert panel. European journal of haematology. 2018 Dec;
[PubMed PMID: 30171728]
[31]
Warkentin TE,Greinacher A, Management of heparin-induced thrombocytopenia. Current opinion in hematology. 2016 Sep;
[PubMed PMID: 27380556]
Level 3 (low-level) evidence
[32]
George JN, Nester CM. Syndromes of thrombotic microangiopathy. The New England journal of medicine. 2014 Aug 14:371(7):654-66. doi: 10.1056/NEJMra1312353. Epub
[PubMed PMID: 25119611]
[33]
George JN,Nester CM,McIntosh JJ, Syndromes of thrombotic microangiopathy associated with pregnancy. Hematology. American Society of Hematology. Education Program. 2015;
[PubMed PMID: 26637783]
[34]
Provan D,Stasi R,Newland AC,Blanchette VS,Bolton-Maggs P,Bussel JB,Chong BH,Cines DB,Gernsheimer TB,Godeau B,Grainger J,Greer I,Hunt BJ,Imbach PA,Lyons G,McMillan R,Rodeghiero F,Sanz MA,Tarantino M,Watson S,Young J,Kuter DJ, International consensus report on the investigation and management of primary immune thrombocytopenia. Blood. 2010 Jan 14;
[PubMed PMID: 19846889]
Level 3 (low-level) evidence
[35]
Neunert C,Lim W,Crowther M,Cohen A,Solberg L Jr,Crowther MA, The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. Blood. 2011 Apr 21;
[PubMed PMID: 21325604]
Level 1 (high-level) evidence
[36]
Hviid A,Mølgaard-Nielsen D, Corticosteroid use during pregnancy and risk of orofacial clefts. CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne. 2011 Apr 19;
[PubMed PMID: 21482652]
[37]
Nguyen TG,Ward CM,Morris JM, To B or not to B cells-mediate a healthy start to life. Clinical and experimental immunology. 2013 Feb;
[PubMed PMID: 23286939]
[39]
Scully M,Knöbl P,Kentouche K,Rice L,Windyga J,Schneppenheim R,Kremer Hovinga JA,Kajiwara M,Fujimura Y,Maggiore C,Doralt J,Hibbard C,Martell L,Ewenstein B, Recombinant ADAMTS-13: first-in-human pharmacokinetics and safety in congenital thrombotic thrombocytopenic purpura. Blood. 2017 Nov 9;
[PubMed PMID: 28912376]
[40]
Scully M,Cataland SR,Peyvandi F,Coppo P,Knöbl P,Kremer Hovinga JA,Metjian A,de la Rubia J,Pavenski K,Callewaert F,Biswas D,De Winter H,Zeldin RK, Caplacizumab Treatment for Acquired Thrombotic Thrombocytopenic Purpura. The New England journal of medicine. 2019 Jan 24
[PubMed PMID: 30625070]
[41]
Rathbone J,Kaltenthaler E,Richards A,Tappenden P,Bessey A,Cantrell A, A systematic review of eculizumab for atypical haemolytic uraemic syndrome (aHUS). BMJ open. 2013 Nov 4;
[PubMed PMID: 24189082]
Level 1 (high-level) evidence
[42]
Wijnsma KL,Ter Heine R,Moes DJAR,Langemeijer S,Schols SEM,Volokhina EB,van den Heuvel LP,Wetzels JFM,van de Kar NCAJ,Brüggemann RJ, Pharmacology, Pharmacokinetics and Pharmacodynamics of Eculizumab, and Possibilities for an Individualized Approach to Eculizumab. Clinical pharmacokinetics. 2019 Jul;
[PubMed PMID: 30758736]
[43]
Sarno L,Tufano A,Maruotti GM,Martinelli P,Balletta MM,Russo D, Eculizumab in pregnancy: a narrative overview. Journal of nephrology. 2019 Feb;
[PubMed PMID: 30159857]
Level 3 (low-level) evidence
[44]
Stefanovic V, The Extended Use of Eculizumab in Pregnancy and Complement Activation⁻Associated Diseases Affecting Maternal, Fetal and Neonatal Kidneys-The Future Is Now? Journal of clinical medicine. 2019 Mar 24;
[PubMed PMID: 30909646]
[45]
De Carolis S,di Pasquo E,Rossi E,Del Sordo G,Buonomo A,Schiavino D,Lanzone A,De Stefano V, Fondaparinux in pregnancy: Could it be a safe option? A review of the literature. Thrombosis research. 2015 Jun;
[PubMed PMID: 25912931]
[46]
Ciurzyński M,Jankowski K,Pietrzak B,Mazanowska N,Rzewuska E,Kowalik R,Pruszczyk P, Use of fondaparinux in a pregnant woman with pulmonary embolism and heparin-induced thrombocytopenia. Medical science monitor : international medical journal of experimental and clinical research. 2011 May;
[PubMed PMID: 21525816]
[47]
Efird LE,Kockler DR, Fondaparinux for thromboembolic treatment and prophylaxis of heparin-induced thrombocytopenia. The Annals of pharmacotherapy. 2006 Jul-Aug;
[PubMed PMID: 16788093]